Current and future management of infections due to methicillin-resistant staphylococci infections: The role of quinupristin/dalfopristin

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue TOPIC A, 1999, Pages 11-18

  Pechere J C ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; EUROPE; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; JAPAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; REVIEW; SKIN INFECTION; STRAIN DIFFERENCE; UNITED STATES;

EID: 0344418717     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.suppl_1.11     Document Type: Review

References (57)

1. Wilkinson, B. J., Maxwell, S. & Schaus, S. M. (1980). Classification and characteristics of coagulase-negative, methicillin-resistant staphylococci. Journal of Clinical Microbiology 12, 161-6.
2. Hiramatsu, K., Hanaki, H., Ino, T., Yubuta, K., Oguri, T. & Tenover, F. C. (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40, 135-6.
3. Centers for Disease Control and Prevention. (1997). Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity and Mortality Weekly Report 46, 765-6.
4. Centers for Disease Control and Prevention. (1997). Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity and Mortality Weekly Report 46, 813-5.
5. Bouanchaud, D. H. (1997). In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 15-21.
6. Finch, R. G. (1996). Antibacterial activity of quinupristin-dalfopristin. Drugs 52, Suppl. 1, 31-7.
7. Jones, R. N., Kehrberg, E. N., Erwin, M. E. & Anderson, S. C. (1994). Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study of the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group. Diagnostic Microbiology and Infectious Disease 19, 203-15.
8. Vincent, J. L., Bihari, D. J., Suter, P. M., Bruining, H. A., White, J., Nicolas-Chanoin, M. H. et al. (1995). The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Journal of the American Medical Association 274, 639-44.
9. Skov, R., Gottschau, A., Skinhøj, P., Frimodt-Møller, N., Rosdahl, V. T. & Espersen, F. (1995). Staphylococcus aureus bacteraemia: a 14-year nationwide study in hematological patients with malignant disease or agranulocytosis. Scandinavian Journal of Infectious Diseases 27, 563-8.
10. Vallés, J., León, C. & Alvarez-Lerma, F. (1997). Nosocomial bacteraemia in critically ill patients: A multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of Sociedad Española de Medicina Intensiva y Unidades Coronarias (SEMIUC). Clinical Infectious Disease 24, 387-95.
11. Baquero, F. (1997). Gram-positive resistance: challenge for the development of new antibiotics. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 1-6.
12. Jarvis, W. R. & Martone, W. J. (1992). Predominant pathogens in hospital infections. Journal of Antimicrobial Chemotherapy 29, Suppl. A, 19-24.
13. Spencer, R. C. (1996). Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. European Journal of Clinical Microbiology and Infectious Diseases 15, 281-5.
14. Schaberg, D. R., Culver, D. H. & Gaynes, R. P. (1991). Major trends in microbial etiology of nosocomial infection. American Journal of Medicine 91, Suppl. 3B, 72-5S.
15. Vazquez, F., Mendoza, M. C., Villar, M. H., Perez, F. & Mendez, F. J. (1994). Survey of bacteraemia in a Spanish hospital over a decade (1981-1990). Journal of Hospital Infection 26, 111-21.
16. Jones, R. N. (1996). Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. American Journal of Medicine 100, Suppl. 6A, 3-12S.
17. Turnidge, J. & Grayson, M. L. (1993). Optimum treatment of staphylococcal infections. Drugs 45, 353-66.
18. Polk, R. E. (1998). Red man syndrome. Annals of Pharmacotherapy 32, 840.
19. Johnson, A. P., Uttley, A. H., Woodford, N. & George, R. C. (1990). Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clinical Microbiology Reviews 3, 280-91.
20. Michel, M. & Gutmann, L. (1997). Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 349, 1901-6.
21. Thornsberry, C. (1996). Emerging resistance in clinically important Gram-positive cocci. Western Journal of Medicine 164, 28-32.
22. Christensen, K. J. & Gubbins, P. O. (1996). Treatment of vancomycin-resistant staphylococcal infections. Annals of Pharmacotherapy 30, 288-90.
23. Centers for Disease Control and Prevention. (1997). Interim guideline for prevention and control of staphylocccal infection associated with reduced susceptibility to vancomycin. Morbidity and Mortality Weekly Report 46, 626-8, 635.
24. Ploy, M. C., Grelaud, C., Martin, C., de Lumley, L. & Denis, F. (1998). First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351, 1212.
25. Mainardi, J. L., Schlaes, D. M., Goering, R. V., Schlaes, J. H., Acar, J. F. & Goldstein, F. W. (1995). Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. Journal of Infectious Diseases 171, 1646-50.
26. Noble, W. C., Virani, Z. & Cree, R. G. A. (1992). Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiology Letters 93, 195-8.
27. Josefson, D. (1997). Vancomycin resistant Staphylococcus aureus reported. British Medical Journal 315, 700.
28. Fagon, J. Y., Maillet, J. M. & Novara, A. (1998). Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission. American Journal of Medicine 104, Suppl. 5A, 17-23S.
29. Rahman, M. (1998). Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections. Journal of Antimicrobial Chemotherapy 41, 325-8.
30. Tally, F. T., Ellestad, G. A. & Testa, R. T. (1995). Glycylcyclines: a new generation of tetracyclines. Journal of Antimicrobial Chemotherapy 35, 449-52.
31. Giamarello-Bourboulis, E. J., Grecka, P., Galani, I. & Giamarello, H. (1997). Comparative in vitro activity and killing effect of trovafloxacin, DU-6859a, levofloxacin and sparfloxacin against Staphylococcus aureus. Focus on methicillin-resistant isolates. Clinical Drug Investigation 14, 330-6.
32. Harrington, G. D., Zarins, L. T., Ramsey, M. A., Bradley, S. F. & Kaufman, C. A. (1995). Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin. Diagnostic Microbiology and Infectious Disease 21, 27-31.
33. Berthaud, N., Huet, Y., Diallo, N. & Desnottes, J. F. (1997). Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 93-8.
34. Berthaud, N., Montay, G., Conard, B. J. & Desnottes, J. F. (1995). Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia. Journal of Antimicrobial Chemotherapy 36, 365-73.
35. Brumfitt, W., Hamilton-Miller, J. M. T. & Shah, S. (1992). In-vitro activity of RP 59500, a new semi-synthetic streptogramin antibiotic, against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 29-37.
36. Chambers, H. F. (1992). Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 117-22.
37. Chin, N. X. & Neu, H. C. (1992). Post-antibiotic effect of the new streptogramin RP 59500. European Journal of Clinical Microbiology and Infectious Diseases 11, 642-5.
38. Dowzicky, M., Nadler, H., Feger, C., Talbot, G., Bompart, F. & Pearce, M. (1998). Evaluation of in vitro activity of quinupristin/ dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. American Journal of Medicine 104, 345-425.
39. Hamilton-Miller, J. M. T. & Shah, S. (1997). Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 103-8.
40. Hoban, D. J., Weshnoweski, B., Palatnick, L., Zhanel, C. G. & Davidson, R. J. (1992). In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 59-65.
41. Inoue, M., Okamoto, R., Okubo, T., Inoue, K. & Mitsuhashi, S. (1992). Comparative in-vitro activity of RP 59500 against clinical bacterial isolates. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 45-51.
42. Low, D. E. & Nadler, H. L. (1997). A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 53-8.
43. Neu, H. C., Chin, N. X. & Gu, J. W. (1992). The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP54476, alone and in combination. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 83-94.
44. Qadri, S. M. H., Ueno, Y., Mostafa, F. M. A. & Halim, M. (1997). In vitro activity of quinupristin/dalfopristin, RP59500, against Gram-positive clinical isolates. Chemotherapy 43, 94-9.
45. Shonekan, D., Handwerger, S. & Mildvan, D. (1997). Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 39, 405-9.
46. Verbist, L. & Verhaegen, J. (1992). Comparative in-vitro activity of RP 59500. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 39-44.
47. Carbon, C. (1997). Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 115-9.
48. Entenza, J. M., Drugeon, H., Glauser, M. P. & Moreillon, P. (1995). Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrobial Agents and Chemotherapy 39, 1419-24.
49. Fantin, B., Leclercq, R., Ottaviani, M., Vallois, J.-M., Maziere, B., Duval, J. et al. (1994). In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrobial Agents and Chemotherapy 38, 432-7.
50. Fantin, B., Leclercq, R., Merlé, Y., Saint-Julien, L., Veyrat, C., Duval, J. et al. (1995). Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 400-5.
51. Rybak, M. J., Houlihan, H. H., Cercier, R.-C. & Kaatz, G. W. (1997). Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrobial Agents and Chemotherapy 41, 1359-63.
52. Nichols, R., for the US Synercid SSSI Study Group (1997). Randomized, comparative, multicenter, open study of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (oxacillin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2319. International Society of Chemotherapy.
53. Beal, J., for the Global Synercid SSSI Study Group (1997). Randomized, comparative, multicenter, open study of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (cefazolin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2318. International Society of Chemotherapy.
54. Nichols, R. L. (1999). Optimal treatment of complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 44, Topic A, 19-23.
55. Fagon, J.-Y., for the Global Synercid NP Study Group. (1997). Randomized, comparative, multicenter, open study of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) plus aztreonam versus vancomycin plus aztreonam in the treatment of Gram-positive nosocomial pneumoniae (NP). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2315, p. 74. International Society of Chemotherapy.
56. Talbot, G. H., Barriere, S., Cerwinka, S., Kreter, B., Lilienthal, F., Nadler, H. et al. (1997). Efficacy of quinupristin/dalfopristin (Synercid, RP 59500) in the treatment of patients with positive blood cultures in global phase III studies. In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2317. International Society of Chemotherapy.
57. Raad, I., for the Global Synercid CRGPB Study Group. (1997). Dose-ranging, randomized, multicenter, open phase II study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) versus vancomycin in the treatment of catheter-related, Gram-positive bacteremia (CRGPB). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2319. International Society of Chemotherapy.